. Translational study of Alzheimer's disease (AD) biomarkers from brain tissues in AβPP/PS1 mice and serum of AD patients. J Alzheimers Dis. 2015;45(1):269-82. PubMed.


Please login to recommend the paper.


  1. The Sun et al. paper shows that serum cathepsin B levels are higher in Alzheimer's disease (AD) patients than normal controls and that higher serum cathepsin B levels are correlated with reduced cognitive ability in AD patients. These data corroborate similar findings by Sundelof et al. and provide added support for serum cathepsin B being a possible AD biomarker. 

    Moreover, the paper shows that hippocampal cathepsin B levels are elevated in the cortices and hippocampi of double transgenic APPSwe/PSEN1 AD mice relative to wild-type mice. These data correlate with the increased cathepsin B gene expression in transgenic 5XFAD AD mice found by Bouter et al.  Thus, elevated cathepsin B levels have now also been shown to occur in several AD mouse models.


    . Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. Front Aging Neurosci. 2014;6:75. Epub 2014 Apr 16 PubMed.

    . Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis. 2010;22(4):1223-30. PubMed.

Make a Comment

To make a comment you must login or register.